Why did you say "No" when you are basically agreeing with me? lol
You're right. I read it backwards. My bad.
True, but when vaping all but disappears, an approved 'smoking cessation' vape device could be released into to a near vacuum, so they can already make money. Once on the market as an "approved" NRT, they won't market for off-label use directly, just encourage and fund studies that show other benefits (there are a number already) and let it happen.
Yes, but there are already a nasal and now a mouth spray (the mouth spray I believe is pretty new so they're protected on that one as brand name only for quite a while) as well as a nicotine inhaler, which is shaped like a fake cigarette and was a lousy product as it was like sucking though a straw with no real satisfaction trying to get the nic out.
For a smoking cessation device that works like a current vape system of heating and vaporizing a nic solution they'd have to go the NDA route, which is a fortune. The only difference to say IQOS, would be instead of modified risk harm reduction product, is the ability to say it's smoking cessation product. I'm not sure how many people would even be able to tell the difference if both are for sale without any prescription and even sold next to each other (assuming the Nicotrol Vape went for mass market sales). And if stuff like Vuse (already filed a PMTA for) and Blu are out there, I'm not sure Pfizer would want to even get into the kind of mega marketing campaign they'd need to.
The idea behind the whole Tobacco Institute PMTA structure was to avoid smoking cessation claims, as that belonged in another part of the FDA, and they were already told you couldn't treat something like vaping as a new drug. While a PMTA appears mountainous to tackle for a small vape company (even the big players who are non-BT) is a fraction of an NDA and something BT is more than happy to generate. While that 150,000 page submission for Vuse likely cost in the low eight figures, it's less than a tenth of an NDA, and a perfectly acceptable amount for a BT company. Is Pfizer really going to jump in with their own nic vape for smoking cessation device when it will cost them nine figures for the approval process? I can't see them bothering with it.
That said, you're right, they have enough nicotine delivery products on the market that should studies support new, off label uses, they'll still benefit without tackling the "vaping as a smoking cessation" approval process. Let alone nicotine for Alzheimer's. Unless they can come up with a synthetic nicotine derivative that's just a different enough molecule for patenting, but that works in clinical studies. Then they would get to selling it for a ridiculous amount of money as a new drug approved for Alzheimer's disease. Which I have no doubt they're already working on.